Things are definitely not perfect for Accuray (ARAY) yet, but the story continues to improve on a quarter by quarter basis. Assuming that the company can successfully convert orders to installations and revenue, the company is gaining share from Varian (VAR) and Elekta (OTCPK:EKTAY) and rebuilding credibility that this can once again become a med-tech growth story.
Many things can still go wrong, as the company's order level is still below where it needs to be to be a viable business and the long-term margin structure is a significant unknown. This is also still a volatile stock, as investors have seen these shares trade down recently on worries about reimbursement in...
Only subscribers can access this article, which is part of the PRO research library covering 3,608 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: